PA8595001A1 - Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) - Google Patents
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)Info
- Publication number
- PA8595001A1 PA8595001A1 PA20048595001A PA8595001A PA8595001A1 PA 8595001 A1 PA8595001 A1 PA 8595001A1 PA 20048595001 A PA20048595001 A PA 20048595001A PA 8595001 A PA8595001 A PA 8595001A PA 8595001 A1 PA8595001 A1 PA 8595001A1
- Authority
- PA
- Panama
- Prior art keywords
- tgf
- growth factor
- transforming growth
- inhibitors
- heteroaromatic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
SE DESCRIBEN NUEVOS COMPUESTOS HETEROAROMATICOS CONDENSADOS, INCLUIDOS SUS DERIVADOS, INTERMEDIOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS 5 QUE LOS CONTIENEN Y SU USO MEDICINAL. LOS COMPUESTOS DE LA PRESENTE INVENCION SON POTENTES INHIBIDORES DE LA RUTA SENALIZADORA DEL FACTOR DE CRECIMIENTO TRANSFORMANTE ("TGF")-B. SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES CON TGF-B INCLUIDAS, POR EJEMPLO, CANCER Y ENFERMEDADES FIBROTICAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45168303P | 2003-03-04 | 2003-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8595001A1 true PA8595001A1 (es) | 2004-09-28 |
Family
ID=32962623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20048595001A PA8595001A1 (es) | 2003-03-04 | 2004-01-30 | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
Country Status (14)
Country | Link |
---|---|
US (2) | US7417041B2 (es) |
EP (1) | EP1601676A2 (es) |
JP (1) | JP2006519249A (es) |
AR (1) | AR043449A1 (es) |
BR (1) | BRPI0407999A (es) |
CA (1) | CA2517933C (es) |
GT (1) | GT200400032A (es) |
MX (1) | MXPA05008148A (es) |
NL (1) | NL1025623C2 (es) |
PA (1) | PA8595001A1 (es) |
PE (1) | PE20050306A1 (es) |
TW (1) | TW200504069A (es) |
UY (1) | UY28214A1 (es) |
WO (1) | WO2004078110A2 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
KR20050057392A (ko) * | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인크. | 전환성장인자(tgf) 억제제로서의 신규한 이미다졸 화합물 |
CA2496295C (en) * | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
EP1804801A2 (en) * | 2004-10-15 | 2007-07-11 | Biogen Idec MA, Inc. | Methods of treating vascular injuries |
WO2006070943A1 (ja) * | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
WO2007028051A2 (en) * | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
US20070142376A1 (en) * | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
JP5292102B2 (ja) * | 2005-12-21 | 2013-09-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チロシンキナーゼ調節剤としてのトリアゾロピリダジン類 |
CN101553224A (zh) * | 2006-10-06 | 2009-10-07 | 艾博特公司 | 新型咪唑并噻唑和咪唑并唑 |
MY188335A (en) | 2006-11-22 | 2021-11-30 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
US20080249305A1 (en) * | 2007-03-27 | 2008-10-09 | Calderwood David J | Novel imidazole based heterocycles |
UA101611C2 (ru) | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
CA2688823A1 (en) * | 2007-05-21 | 2008-11-27 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
US20100179143A1 (en) * | 2007-05-29 | 2010-07-15 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
JP5410431B2 (ja) * | 2007-09-27 | 2014-02-05 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 |
WO2010012345A1 (en) * | 2008-07-29 | 2010-02-04 | Merck Patent Gmbh | Imidazothiadiazoles derivatives |
KR101727264B1 (ko) | 2009-04-02 | 2017-04-14 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | 이미다조〔2,1-b〕〔1,3,4〕티아디아졸 유도체 |
FR2945289A1 (fr) * | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
CA2777739A1 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
JP5641664B2 (ja) | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用 |
MX2012006994A (es) | 2009-12-18 | 2012-07-03 | Mitsubishi Tanabe Pharma Corp | Agente antiplaquetas novedoso. |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
KR101938368B1 (ko) | 2011-07-13 | 2019-01-14 | 주식회사 티움바이오 | Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸 |
US9637723B2 (en) | 2012-05-30 | 2017-05-02 | Cornell University Q | Generation of functional and durable endothelial cells from human amniotic fluid-derived cells |
ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
CA2914615C (en) | 2013-06-05 | 2023-10-17 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
SI3089971T1 (sl) | 2014-01-01 | 2020-11-30 | Medivation Technologies Llc | Spojine in postopki za uporabo |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
WO2016081364A1 (en) * | 2014-11-21 | 2016-05-26 | Rigel Pharmaceuticals, Inc. | Fused imidazole derivatives as tgf-beta inhibitors |
TW201630907A (zh) * | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | TGFβR拮抗劑 |
AU2016228584A1 (en) | 2015-03-11 | 2017-10-05 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
EP3894401A2 (en) | 2018-12-11 | 2021-10-20 | Theravance Biopharma R&D IP, LLC | Naphthyridine and quinoline derivatives useful as alk5 inhibitors |
EP4061809A1 (en) | 2019-11-22 | 2022-09-28 | Theravance Biopharma R&D IP, LLC | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (es) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
ZW24186A1 (en) | 1985-12-12 | 1987-07-08 | Smithkline Beckman Corp | Inhibition of the 5-lipoxygenase pathway |
US4719218A (en) * | 1985-12-12 | 1988-01-12 | Smithkline Beckman Corporation | Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor |
US5002941A (en) * | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
IL83467A0 (en) | 1986-08-15 | 1988-01-31 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same |
NZ225967A (en) | 1987-09-02 | 1992-03-26 | Smithkline Beckman Corp | Substituted pyrrolo(1,2-a)imidazole and pyrrolo(1,2-a)pyridine derivatives; pharmaceutical compositions; intermediates |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
RU2249591C2 (ru) | 1997-05-22 | 2005-04-10 | Дж.Д. Серл Энд Ко. | 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38 |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
JP2002502380A (ja) | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | p38キナーゼ阻害剤としてのピラゾール誘導体 |
EP1169317B1 (en) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
WO2002040468A1 (en) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
WO2002062787A1 (en) | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
US20040087623A1 (en) | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
WO2002072576A1 (en) | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
CN1496366A (zh) | 2001-03-09 | 2004-05-12 | �Ʒ� | 作为抗炎剂的***并吡啶 |
DE60205974T2 (de) | 2001-04-04 | 2006-06-29 | Pfizer Products Inc., Groton | Neue Benzotriazole mit entzündungshemmender Wirkung |
WO2003000682A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
WO2004013135A1 (en) | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
GB0217783D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
CA2498237A1 (en) * | 2002-09-13 | 2004-03-25 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
CA2499429C (en) | 2002-09-18 | 2010-09-21 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors |
CA2496295C (en) * | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
AU2003260810A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
AP2005003262A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. |
KR20050057392A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인크. | 전환성장인자(tgf) 억제제로서의 신규한 이미다졸 화합물 |
-
2004
- 2004-01-30 PA PA20048595001A patent/PA8595001A1/es unknown
- 2004-02-20 US US10/783,251 patent/US7417041B2/en not_active Expired - Fee Related
- 2004-02-23 EP EP04713609A patent/EP1601676A2/en not_active Withdrawn
- 2004-02-23 CA CA002517933A patent/CA2517933C/en not_active Expired - Fee Related
- 2004-02-23 JP JP2006506271A patent/JP2006519249A/ja active Pending
- 2004-02-23 BR BRPI0407999-0A patent/BRPI0407999A/pt not_active IP Right Cessation
- 2004-02-23 WO PCT/IB2004/000532 patent/WO2004078110A2/en active Application Filing
- 2004-02-23 MX MXPA05008148A patent/MXPA05008148A/es active IP Right Grant
- 2004-03-01 PE PE2004000223A patent/PE20050306A1/es not_active Application Discontinuation
- 2004-03-02 UY UY28214A patent/UY28214A1/es not_active Application Discontinuation
- 2004-03-02 AR ARP040100654A patent/AR043449A1/es not_active Application Discontinuation
- 2004-03-02 GT GT200400032A patent/GT200400032A/es unknown
- 2004-03-03 TW TW093105533A patent/TW200504069A/zh unknown
- 2004-03-03 NL NL1025623A patent/NL1025623C2/nl not_active IP Right Cessation
-
2008
- 2008-07-23 US US12/178,160 patent/US20080275235A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA05008148A (es) | 2005-09-30 |
US20040176390A1 (en) | 2004-09-09 |
UY28214A1 (es) | 2004-09-30 |
GT200400032A (es) | 2004-10-21 |
PE20050306A1 (es) | 2005-05-16 |
WO2004078110A2 (en) | 2004-09-16 |
JP2006519249A (ja) | 2006-08-24 |
AR043449A1 (es) | 2005-07-27 |
TW200504069A (en) | 2005-02-01 |
CA2517933A1 (en) | 2004-09-16 |
NL1025623A1 (nl) | 2004-09-07 |
CA2517933C (en) | 2009-05-12 |
US20080275235A1 (en) | 2008-11-06 |
BRPI0407999A (pt) | 2006-03-07 |
EP1601676A2 (en) | 2005-12-07 |
WO2004078110A3 (en) | 2004-11-11 |
NL1025623C2 (nl) | 2005-03-14 |
US7417041B2 (en) | 2008-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8595001A1 (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) | |
ECSP055679A (es) | Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf) | |
PA8583401A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
PA8583101A1 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
UY27982A1 (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
PA8582701A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
CY1106468T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
BRPI0408251A (pt) | compostos de pirazina como inibidores do fator de crescimento transformante (tgf) | |
PA8592301A1 (es) | Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
GT200600199A (es) | Diarilsulfonas sulfonamidas y su uso | |
CY1110530T1 (el) | Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων | |
PA8596901A1 (es) | Inhibidores de p38 y metodos de uso de ellos | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
CY1109465T1 (el) | Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης | |
UY27372A1 (es) | Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados | |
CR7748A (es) | Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) | |
DOP2003000713A (es) | Nuevos compuestos de pirarol como inhibidores delfactor de crecimiento transformante (tgf) | |
DOP2003000718A (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
DOP2003000701A (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
CR7749A (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
ECSP055682A (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
DOP2003000719A (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
DOP2003000712A (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
ECSP045431A (es) | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |